Evidence map›Paper›PMID 35410048›Full record

ArticleInternational journal of environmental research and public health2022

Tuberculosis Co-Infection Is Common in Patients Requiring Hospitalization for COVID-19 in Belarus: Mixed-Methods Study.

Yuliia Sereda, Oleksandr Korotych, Dzmitry Klimuk, Dzmitry Zhurkin, Varvara Solodovnikova, Malgorzata Grzemska, Viatcheslav Grankov, Hennadz Hurevich, Askar Yedilbayev, Alena Skrahina

Open access · goldAbstract read
In one paragraph

Article in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Pathogenesis of SARS-CoV-2 andFrontiers in immunology · 2022
    Review
  9. Immunopathogenesis in SARS-CoV-2 andFrontiers in pharmacology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yuliia SeredaWorld Health Organization Regional Office for Europe, Marmorvej 51, DK-2100 Copenhagen, Denmark.ORCID 0000-0002-4017-4561
Oleksandr KorotychWorld Health Organization Regional Office for Europe, Marmorvej 51, DK-2100 Copenhagen, Denmark.
Dzmitry KlimukRepublican Scientific and Practical Centre for Pulmonology and Tuberculosis, 157 Dolginovskij trakt, 220053 Minsk, Belarus.ORCID 0000-0002-0222-5583
Dzmitry ZhurkinRepublican Scientific and Practical Centre for Pulmonology and Tuberculosis, 157 Dolginovskij trakt, 220053 Minsk, Belarus.
Varvara SolodovnikovaRepublican Scientific and Practical Centre for Pulmonology and Tuberculosis, 157 Dolginovskij trakt, 220053 Minsk, Belarus.ORCID 0000-0003-1655-4000
Malgorzata GrzemskaWorld Health Organization Regional Office for Europe, Marmorvej 51, DK-2100 Copenhagen, Denmark.
Viatcheslav GrankovWorld Health Organization Country Office in Belarus, Fabriciusa str. 28 (Room 401), 220007 Minsk, Belarus.ORCID 0000-0001-9891-2718
Hennadz HurevichRepublican Scientific and Practical Centre for Pulmonology and Tuberculosis, 157 Dolginovskij trakt, 220053 Minsk, Belarus.
Askar YedilbayevWorld Health Organization Regional Office for Europe, Marmorvej 51, DK-2100 Copenhagen, Denmark.
Alena SkrahinaRepublican Scientific and Practical Centre for Pulmonology and Tuberculosis, 157 Dolginovskij trakt, 220053 Minsk, Belarus.
Republican Scientific and Practical Centre of Pulmonology and Tuberculosis · BYWorld Health Organization Regional Office for Europe · DKMinistry of Health · BY

Funding

World Health Organization 001
6 · The paper itself

Abstract

A significant drop in tuberculosis (TB) case-finding has been widely reported during the period of the COVID-19 pandemic. To address a decrease in TB notification, Belarus introduced laboratory TB testing in patients with the laboratory-confirmed coronavirus disease 2019 (COVID-19). We conducted a secondary analysis of health records among 844 patients with laboratory-confirmed COVID-19 diagnosis who were admitted to repurposed departments at TB hospitals and who were tested by Xpert MTB/RIF (Cepheid Inc., Sunnyvale, CA, USA) in five Belarus regions between April and October 2021. Quantitative analysis followed by 13 individual interviews with health managers, physicians, and nurses participating in the intervention. Most patients were male (64%) and mean age was 43.5 ± 16 years. One in twenty (n = 47, 5.6%) patients were co-infected with active pulmonary TB, and over one-third of them (n = 18) had rifampicin resistance. In-hospital mortality was comparable in patients with and without TB co-infection (2.1% and 2.3% respectively, p > 0.99). Laboratory TB testing among patients with COVID-19 at repurposed departments of TB hospitals is feasible in Belarus and may improve TB case-finding.

Indexed as

Antibiotics, AntitubercularCoinfectionCOVID-19Latent TuberculosisMycobacterium tuberculosisTuberculosisAdultCOVID-19 TestingHospitalizationHumansMaleMiddle AgedPandemicsRepublic of BelarusRifampinSensitivity and SpecificityAntibiotics, AntitubercularRifampincase-findingCOVID-19Eastern Europeoperational researchrifampicin resistancetuberculosisXpert MTB/RIF

Identifiers

PMID35410048
PMCPMC9028713
OpenAlexW4223555476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.